

CV ROCÍO CARBONERO - SERVICIO DE ONCOLOGÍA HOSPITAL 12 DE OCTUBRE

Nombre y dos apellidos.	ROCIO GARCIA CARBONERO
Unidad del Servicio a la que está adscrito/a.	UNIDAD DE TUMORES DIGESTIVOS Y NEUROENDOCRINOS
Cargo/s actuales, tanto en el Servicio de Oncología del Hospital 12 de Octubre como en sociedades científicas, otras entidades asociativas, grupos de trabajo, universidades si ejerce labor docente en alguna de ellas, comités editoriales, etc. Si de alguna sociedad/entidad asociativa sólo se es miembro, también debe citarse.	<ol style="list-style-type: none"> 1. Coordinadora de la Sección de Tumores Digestivos y Neuroendocrinos del Sº de Oncología Médica, Hospital Universitario 12 de Octubre 2. Directora del Centro de Excelencia para Tumores Neuroendocrinos del Hospital 12 de Octubre, acreditado por la Sociedad Europea de Tumores Neuroendocrinos (ENETS Centre of Excellence) 3. Profesora Titular de la Universidad Complutense de Madrid (UCM) 4. Directora del Master de Tumores Neuroendocrinos de la UCM 5. Jefa de grupo, Laboratorio de Oncología Traslacional en Tumores Digestivos y Neuroendocrinos, Centro de Oncología Experimental, Instituto de Investigación Hospital 12 de Octubre (Imas12) 6. Presidenta de la Sociedad Europea de Tumores Neuroendocrinos (ENETS) 7. Faculty coordinator para Tumores Neuroendocrinos y Endocrinos de la Sociedad Europea de Oncología Médica (ESMO) 8. Ex-Presidenta del Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) (2011-2019). Actualmente miembro de la Junta Directiva GETNE. 9. Miembro del TTD, SEOM, ESMO Y ASCO 10. Miembro del Comité Médico Asesor de la Asociación de Pacientes con Tumores Neuroendocrinos NET España
Formación académica (titulación/es, centro en el que se obtuvo y año de finalización).	<ul style="list-style-type: none"> • Licenciada en Medicina y Cirugía, Universidad Autónoma de Madrid (1992) • Especialista en Oncología Médica, Hospital 12 de Octubre de Madrid (1997) • Doctora en Medicina, UCM (1998) • Estudios de Postgrado en Estadística para ciencias de la salud, Universidad Autónoma de Barcelona (1998) • ECFMG/USMLE (Educational Commission for Foreign Medical Graduates /U.S. Medical Licence Exams)(1999) • Fellowship en Farmacología Clínica y Terapéutica Experimental, Massachusetts General Hospital/Dana Farber Cancer Institute, Universidad de Harvard, Boston, USA (1998-2000) • Experto Universitario en Gestión de Unidades Clínicas, UNED (2003) • Master en Oncología Molecular, CNIO (2007) • Master en protección y experimentación animal para investigadores en ciencias biomédicas, Universidad de Granada (2012)

Publicaciones científicas (nº total, especificando sólo la cifra, y referencias de las más destacadas).

Nº total: 242

Indice H: 68, Indice i10: 235

Publicaciones en primer decil (D1): 63

Publicaciones en primer cuartil (Q1): 132

Publicaciones más destacadas:

1. Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, **Garcia-Carbonero R**, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A; LITESPARK-015 Investigators. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. *N Engl J Med*. 2025 Oct 18. doi: 10.1056/NEJMoa2504964. Epub ahead of print. PMID: 41124218.
2. Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, **Garcia-Carbonero R**, Teulé A, Custodio A, Jimenez-Fonseca P, Lopez C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, Garcia-Alvarez A, Alonso-Gordo T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E. Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). *Clin Cancer Res*. 2025 Sep 12. doi: 10.1158/1078-0432.CCR-25-2143. Epub ahead of print. PMID: 40938918.
3. Riechelmann RP, **Garcia-Carbonero R**. The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors. *Ann Oncol*. 2025 Dec 31:S0923-7534(25)04786-6. doi: 10.1016/j.annonc.2025.09.015. Epub ahead of print. PMID: 41111033.
4. Rubio-Cuesta B, Carretero-Puche C, Llamas P, Sarmentero J, Gil-Calderon B, Lens-Pardo A, Antón-Pascual B, Rubio-González E, Cámara-Jurado M, Salamanca J, Rueda-Fernández D, Delcuratolo MD, Soldevilla B, **Garcia-Carbonero R**. Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. *Br J Cancer*. 2025 Aug;133(3):404-419. doi: 10.1038/s41416-025-03058-6. Epub 2025 Jun 6. PMID: 40481178; PMCID: PMC12322152.
5. Eng C, Dasari A, Lonardi S, **Garcia-Carbonero R**, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara F, Schelman W, Pallai R, Tabertero J. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. *Oncologist*. 2025 Mar 10;30(3):oyae360. doi: 10.1093/oncolo/oyae360. PMID: 40163688; PMCID: PMC11957243.
6. André T, Elez E, Lenz HJ, Jensen LH, Toucheffeu Y, Van Cutsem E, **Garcia-Carbonero R**, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. *Lancet*. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4. Epub 2025 Jan 25. Erratum in: *Lancet*. 2025 Mar 1;405(10480):700. doi: 10.1016/S0140-6736(25)00352-6. PMID: 39874977.
7. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, **Garcia-Carbonero R**, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. *N Engl J Med*. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. PMID: 39602630.

8. Sarno F, Tenorio J, Perea S, Medina L, Pazo-Cid R, Juez I, **Garcia-Carbonero R**, Feliu J, Guillen-Ponce C, Lopez-Casas PP, Guerra C, Duran Y, López-Acosta JF, Alonso C, Esquivel E, Dopazo A, Akshinthala D, Muthuswamy SK, Lapunzina P, Bockorny B, Hidalgo M. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. *Clin Cancer Res*. 2025 Jan 17;31(2):278-287. doi: 10.1158/1078-0432.CCR-23-4026. PMID: 39540844; PMCID: PMC11739777.
9. Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, Sevilla I, Benavent M, Alonso-Gordoa T, Custodio A, Anton-Pascual B, Hernando J, Polo E, Castillo-Trujillo OA, Lamas-Paz A, Teijo A, Rodriguez-Gil Y, Soldevilla B, **Garcia-Carbonero R**. Nivolumab plus platinum-doublet chemotherapy in treatment-naïve patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). *Nat Commun*. 2024 Aug 8;15(1):6753. doi: 10.1038/s41467-024-50969-8. PMID: 39117670; PMCID: PMC11310219.
10. Lamberti G, Panzuto F, Pavel M, O'Toole D, Ambrosini V, Falconi M, **Garcia-Carbonero R**, Riechelmann RP, Rindi G, Campana D. Gastric neuroendocrine neoplasms. *Nat Rev Dis Primers*. 2024 Apr 11;10(1):25. doi:10.1038/s41572-024-00508-y. PMID: 38605021.
11. Dasari A, Lonardi S, **Garcia-Carbonero R**, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csósz T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Taberero J, Eng C; FRESKO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESKO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet*. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. PMID: 37331369.
12. Capdevila J, Hernando J, Teule A, Lopez C, **Garcia-Carbonero R**, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. *Nat Commun*. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5. PMID: 37221181; PMCID: PMC10204675.
13. Hidalgo M, **Garcia-Carbonero R**, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tamaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. *Cancer Res Commun*. 2022 Nov 2;2(11):1326-1333. doi: 10.1158/2767-9764.CRC-22-0072. PMID: 36970055; PMCID: PMC10035387.
14. **Garcia-Carbonero R**, Anton-Pascual B, Modrego A, Del Carmen Riesco-Martinez M, Lens-Pardo A, Carretero-Puche C, Rubio-Cuesta B, Soldevilla B. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? *Endocr Rev*. 2023 Jul 11;44(4):724-736. doi: 10.1210/endrev/bnad006. PMID: 36879384; PMCID: PMC10335166.
15. Soldevilla B, Lens-Pardo A, Espinosa-Olarte P, Carretero-Puche C, Molina-Pinelo S, Robles C, Benavent M, Gomez-Izquierdo L, Fierro-Fernández M, Morales-Burgo P, Jimenez-Fonseca P, Anton-Pascual B, Rodriguez-Gil Y, Teijo-Quintans A, La Salvia A, Rubio-Cuesta B, Riesco-Martinez MC, **Garcia-Carbonero R**. MicroRNA signature and integrative omics analyses define prognostic clusters

- and key pathways driving prognosis in patients with neuroendocrine neoplasms. *Mol Oncol*. 2023 Apr;17(4):582-597. doi: 10.1002/1878-0261.13393. Epub 2023 Mar 5. PMID: 36795001; PMCID: PMC10061291.
16. Borbath I, **Garcia-Carbonero R**, Bikmukhametov D, Jimenez-Fonseca P, Castaño A, Barkmanova J, Sedlackova E, Kollár A, Christ E, Kaltsas G, Kos-Kudla B, Maasberg S, Verslype C, Pape UF. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. *Eur J Cancer*. 2022 Jun;168:80-90. doi: 10.1016/j.ejca.2022.03.007. Epub 2022 Apr 23. PMID: 35472579.
 17. **Garcia-Carbonero R**, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N, Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. *J Immunother Cancer*. 2022 Mar;10(3):e003255. doi: 10.1136/jitc-2021-003255. PMID: 35338084; PMCID:PMC8961117.
 18. Bazan-Peregrino M, **Garcia-Carbonero R**, Laquente B, Álvarez R, Mato-Berciano A, Gimenez-Alejandro M, Morgado S, Rodríguez-García A, Maliandi MV, Riesco MC, Moreno R, Ginestà MM, Perez-Carreras M, Gornals JB, Prados S, Perea S, Capella G, Alemany R, Salazar R, Blasi E, Blasco C, Cascallo M, Hidalgo M. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. *J Immunother Cancer*. 2021 Nov;9(11):e003254. doi: 10.1136/jitc-2021-003254. PMID: 35149591; PMCID: PMC8578996.
 19. Grande E, Rodriguez-Antona C, López C, Alonso-Gordoa T, Benavent M, Capdevila J, Teulé A, Custodio A, Sevilla I, Hernando J, Gajate P, Molina-Cerrillo J, Díez JJ, Santos M, Lanillos J, **Garcia-Carbonero R**. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade1-2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. *Oncologist*. 2021 Nov;26(11):941-949. doi: 10.1002/onco.13885. Epub 2021 Jul 14. PMID: 34190375; PMCID: PMC8571752.
 20. **Garcia-Carbonero R**, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, Alvarez-Escuela C, Arístegui M, Bella-Cueto MR, Ferrer-Albiach C, Hanzu FA. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. *Clin Transl Oncol*. 2021 Oct;23(10):1995-2019. doi:10.1007/s12094-021-02622-9. Epub 2021 May 6. PMID: 33959901; PMCID: PMC8390422.
 21. Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, **Garcia-Carbonero R**, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). *J Clin Oncol*. 2021 Jul 10;39(20):2304-2312. doi: 10.1200/JCO.20.03368. Epub 2021 May 4. PMID: 33945297.
 22. Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, **Garcia-Carbonero R**. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. *J Immunother Cancer*. 2021 Mar;9(3):e002068. doi: 10.1136/jitc-2020-002068. PMID: 33688022; PMCID:PMC7944986.
 23. Riesco-Martinez MC, Fernandez-Martos C, Gravalos-Castro C, Espinosa-Olarte P, La Salvia A, Robles-Diaz L, Modrego-Sanchez A, **Garcia-Carbonero R**. Impact of Total Neoadjuvant Therapy vs.

- Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. *Cancers* (Basel). 2020 Dec 5;12(12):3655. doi: 10.3390/cancers12123655. PMID:33291454; PMCID: PMC7762140.
24. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, **Garcia-Carbonero R**, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. *N Engl J Med*. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. PMID: 33264544.
25. Grande E, Teulé A, Alonso-Gordoa T, Jiménez-Fonseca P, Benavent M, Capdevila J, Custodio A, Vera R, Munarriz J, La Casta A, Díez JJ, Gajate P, Molina-Cerrillo J, Matos I, Cristóbal EM, Ruffinelli JC, Palacios J, **Garcia-Carbonero R**. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). *Oncologist*. 2020 Sep;25(9):745-e1265. doi: 10.1634/theoncologist.2020-0033. Epub 2020 Feb 11. PMID: 32045050; PMCID: PMC7485337.
26. Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco MC, Gil-Calderon B, Alvarez-Vallina L, Espinosa-Olarte P, Gomez-Esteves G, Rubio-Cuesta B, Sarmentero J, La Salvia A, **Garcia-Carbonero R**. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. *Eur J Cancer*. 2019 Dec;123:118-129. doi:10.1016/j.ejca.2019.09.008. Epub 2019 Nov 1. PMID: 31678770.
27. Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Díaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, **Garcia-Carbonero R**. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. *J Clin Oncol*. 2019 Oct 1;37(28):2571-2580. doi:10.1200/JCO.19.00980. Epub 2019 Aug 7. PMID: 31390276; PMCID: PMC6768612.
28. Melisi D, **Garcia-Carbonero R**, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Taberero J. Galunisertib plus gemcitabine vs.gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. *Br J Cancer*. 2018 Nov;119(10):1208-1214. doi: 10.1038/s41416-018-0246-z. Epub 2018 Oct 15. PMID: 30318515; PMCID: PMC6251034.
29. Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, **Garcia-Carbonero R**; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology*. 2019;108(1):54-62. doi: 10.1159/000493318. Epub 2018 Aug 28. PMID: 30153658.
30. Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martínez Del Prado MP, Díaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, **Garcia-Carbonero R**. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). *Oncologist*. 2018 Apr;23(4):422-432.

31. Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony L, Kunz P, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, **Garcia-Carbonero R**. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018 Mar;25(3):309-322.
32. Salazar R, **Garcia-Carbonero R**, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klumpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2017 Dec 14. pii: theoncologist.2017-0144. doi: 10.1634/theoncologist.2017-0144. [Epub ahead of print] PubMed PMID: 29242283.
33. **Garcia-Carbonero R**, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30.
34. **Garcia-Carbonero R**, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla J, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants. ENETS Consensus Guidelines for High Grade Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumours and Neuroendocrine Carcinomas (NEC). Neuroendocrinology. 2016;103:186-194. (European guidelines)
35. **Garcia-Carbonero R**, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015 Dec;34(4):823-42.
36. Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodríguez-Antona C, Alonso-Gordoa T, Díez JJ, Carrato A, **Garcia-Carbonero R**. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep;26(9):1987-93.
37. R.J. Mayer, E.V. Cutsem, A. Falcone, T. Yoshino, **R. Garcia-Carbonero**, N. Mizunuma, K. Yamazaki, Y. Shimada, J. Taberero, Y. Komatsu, A. Sobrero, E. Boucher, M. Peeters, B. Tran, H-J Lenz, A. Zaniboni, H. Hochster, J.M. Cleary, Hans Prenen, F. Benedetti, H. Mizuguchi, L. Makris, M. Ito, A. Ohtsu, on behalf of the RECURSE Study Group. TAS-102 monotherapy for metastatic colorectal cancer refractory to standard therapies (RECURSE): a multicenter, randomized, double-blind, phase 3 trial. New England Journal of Medicine 2015 May 14;372(20):1909-19.
38. R. Dienstmann, A. Patnaik, **R. Garcia-Carbonero**, A. Cervantes, M. Benavent, S. Roselló, B. B. J. Tops, R. S. van der Post, G. Argiles, N. J.Ø. Skartved, U. H. Hansen, R. Hald, M. W. Pedersen, M. Kragh, I. D. Horak, S. Braun, E. van Cutsem, A. W. Tolcher, and J. Taberero. Safety and Activity of the First-in-class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery 2015 Jun;5(6):598-609.
39. P. Estevez-Garcia, F. Rivera, S. Molina-Pinelo, M. Benavent, Javier Gómez, Maria Luisa Limón, Maria Dolores Pastor, Julia Martinez-Perez, L. Paz-Ares, A. Carnero and **R. Garcia-Carbonero**. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget 2015 Mar 20;6(8):6151-9.

40. **Garcia-Carbonero R**, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J. An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer. *Oncologist*. 2014 Apr;19(4):350-1.
41. **Garcia-Carbonero R**, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. *Lancet Oncology* 2013 Aug;14(9):e358-69.
42. J. Tabernero, **R. Garcia-Carbonero**, J. Cassidy, A. Sobrero, E. Van Cutsem, C.H. Köhne, S. Tejpar, O. Gladkov, I. Davidenko, R. Salazar, L. Vladimirova, S. Cheporov, O. Burdaeva, F. Rivera, L. Samuel, I. Bulavina, V. Potter, Y.L. Chang, N. A. Lokker, P. J. O'Dwyer. Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. *Clin Cancer Res* 2013 May 1;19(9):2541-50.
43. **Garcia-Carbonero R**, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A and Salazar R. Incidence, Patterns of Care and Prognostic Factors for Outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). *Ann Oncol* 2010 Sep;21(9):1794-803.
44. **R. Garcia-Carbonero**, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, U. Matulonis, R.G. Maki, T. Lopez, T.A. Puchalski, M. A. Sancho, J. Gomez, C. Guzman, J. Jimeno, and G.D. Demetri. Phase II and pharmacokinetic study of Ecteinascidin-743 (ET-743) in patients with progressive sarcomas of soft tissues following failure of conventional chemotherapy. *J Clin Oncol* Apr 15;22(8):1480-90, 2004.
45. **R. Garcia-Carbonero** and J.G. Supko. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. *Clinical Cancer Res* 2002 Mar; 8(3):641-61.
46. **R. Garcia-Carbonero**, J.I.Mayordomo, M.V.Tornamira, M.Lopez-Brea, A.Rueda, V.Guillem, A.Arcediano, A.Yubero, F.Rivera, C.Gomez, A.Tres, J.L.Perez-Gracia, C.Lumbreras, H.Cortes-Funes and L.Paz-Ares. Granulocyte colony-stimulating factor (G-CSF) in the treatment of high-risk febrile neutropenia: Results of a multicenter randomized phase III trial. *J Natl Cancer Inst* 2001 Jan; 93(1): 31-38.
47. **R. Garcia-Carbonero**, M. Hidalgo, L. Paz-Ares, J. Calzas, H. Gomez, JA. Guerra, R. Hitt, J. Hornedo, R. Colomer and H. Cortés-Funes: Patient selection in High-Dose Chemotherapy Trials: Relevance in High-Risk Breast Cancer. *J Clin Oncol* 15: 3178-3184, 1997.